Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2026, and recent business progress.

Conference Call and Webcast Information:

• Date: Tuesday, May 12, 2026 at 4:30 PM ET
• Participant Dial-in (US): 1-800-717-1738
• Participant Dial-in (International): 1-646-307-1865
• Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
[email protected]

Media Inquiries:
Corporate Communications
[email protected]

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Rocket Lab Shatters Responsive Space Record: Launches U.S. Space Force VICTUS HAZE Mission in 16 Hours 42 Minutes
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge